canyon landscape

T2 Protect AD

Preclinical models suggest that riluzole, the active metabolite of BHV-4157, may protect from AD-related pathology and cognitive dysfunction. Titrated dose of BHV-4157 to 280 mg, or placebo, taken orally once daily. Duration of treatment is 48 weeks. There is also a screening period of up to 42 days; and a 4-week post-treatment observation period.

Status
Open and enrolling subjects.
Location
Phoenix, Arizona
Age Range
  • 50-85
Total Participants
292
Primary Sponsor
Biohaven Pharmaceuticals, Inc.
Additional Sponsor(s)
Alzheimer's Disease Cooperative Study (ADCS)